

Thromboxane A₂ Synthetase Inhibitors with Histamine H₁-Blocking Activity: Synthesis and Evaluation of a New Series of Indole Derivatives¹⁾

Shoji KAMIYA,* Hiroshi MATSUI, Hiroaki SHIRAHASE, Shohei NAKAMURA, Katsuo WADA, Mamoru KANDA, Hisanobu SHIMAJI, and Nobuharu KAKEYA

Research Laboratories, Kyoto Pharmaceutical Industries, Ltd., 38 Tukinowa-cho, Nisinokyo, Nakakyo-ku, Kyoto 604, Japan. Received February 20, 1995; accepted May 31, 1995

A novel series of N-substituted 3-(1*H*-imidazol-1-ylmethyl)indole carboxylic acid derivatives were prepared and evaluated for thromboxane A₂ (TXA₂) synthetase-inhibitory and histaminergic H₁-blocking activity. Among the compounds synthesized, indole-6-carboxylic acid derivatives showed higher activities than the other positional isomers of carboxylic acid. 1-[3-(4-Benzhydryl-1-piperazinyl)propyl]-3-(1*H*-imidazol-1-ylmethyl)-1*H*-indole-6-carboxylic acid (**12**) had the strongest thromboxane synthetase inhibitory activity (IC₅₀ = 5 × 10⁻⁸ M) and H₁-blocking activity (IC₅₀ = 8 × 10⁻⁹ M).

Key words TXA₂ synthetase inhibitor; H₁-blocker; bronchoconstriction; structure-activity relationship; KY-234

Thromboxane A₂ (TXA₂) and histamine are important chemical mediators involved in asthma. Ozagrel, a TXA₂ synthetase inhibitor,²⁾ and terfenadine, a non-sedative H₁-blocker,³⁾ have been used in the treatment of asthma. We hypothesized that a compound with both TXA₂ synthetase-inhibitory and H₁-blocking activities would provide more effective protection against asthma than a simple TXA₂ synthetase inhibitor or H₁-blocker. We have therefore synthesized a novel series of indole derivatives with substituents which might be suitable for TXA₂ synthetase inhibitors⁴⁾ and histamine H₁-blockers.⁵⁾ N-Substituted 3-(1*H*-imidazol-1-ylmethyl)indole (**9**) showed a weak inhibitory effect on arachidonate-induced platelet aggregation, which is TXA₂-dependent⁶⁾ and histamine-induced contraction of guinea pig trachea, which is mediated by H₁-receptors.⁷⁾ To enhance both activities, a carboxylic acid moiety was introduced into the indole ring at the 4, 5, 6 or 7 position of **9** and various substituents at the N₁-position. Among these compounds, 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1*H*-imidazol-1-ylmethyl)-1*H*-indole-6-carboxylic acid (**12**) had the strongest TXA₂ synthetase-inhibitory and H₁-blocking activities. Herein, the synthesis, structure-activity relationship and pharmacological evaluation of this novel series of indole derivatives are described.

Chemistry

Chart 1 shows the general synthetic pathway for preparation of the target compounds. The indole-carboxylic acid methylester (**4**) was prepared according to the Leimgruber-Batcho indole synthesis.⁸⁾ The methylester (**2**) was prepared by acid-catalyzed esterification of the corresponding methyl-nitrobenzoic acid (**1**) in MeOH, and reaction of **2** with *N,N*-dimethylformamide dimethylacetal in DMF at 100 °C afforded **3**, which was converted to the indole methylester (**4**) by catalytic reduction using 5% Pd-C. Compound **6** was prepared from a Mannich base by refluxing with imidazole in xylene.⁴⁾ The Mannich base (**5**) was obtained by treatment of the corresponding derivative (**4**) with 35% aqueous HCHO and 50% aqueous HN(CH₃)₂ in AcOH-dioxane at 20 °C. Treatment of **6** with NaH in DMF followed by dihalogenoalkane gave

the N-halogenoalkyl-indole (**7**) and condensation of appropriate amines with **7** afforded **8**. The carboxylic acids (**10**–**23**) were prepared by base hydrolysis of the esters (**8**).

Pharmacological Results and Discussion

In the present study, the inhibitory activity of derivatives towards TXA₂ synthetase and H₁-receptors was estimated





Chart 1

* To whom correspondence should be addressed.

in terms of the effect on arachidonate-induced, TXA₂-dependent aggregation of rabbit platelets and histamine-induced, H₁-mediated contraction of guinea pig trachea. Tables 1 and 2 summarize the results. Ozagrel (10⁻⁶–10⁻⁴ M), a known TXA₂ synthetase inhibitor, concentration-dependently inhibited the arachidonate-induced aggregation, but did not affect the histamine-induced contraction of tracheal preparations. None of the compounds synthesized, or ozagrel, had any effect on ADP-induced, TXA₂-independent platelet aggregation. Pylramine (10⁻⁹–10⁻⁷ M), an H₁-blocker, concentration-dependently relaxed the tracheal preparations contracted with histamine. Cimetidine (10⁻⁵ M), an H₂-blocker, failed to affect the histamine-induced contraction.

Introduction of a carboxylic acid moiety at the 4-position (**10**) or 5-position (**11**) of the indole ring decreased the inhibitory effect on arachidonate-induced platelet aggregation by more than 100-fold and its introduction at the 7-position (**13**) decreased the effect by 5-fold. In contrast, the isomer with COOH at the 6-position (**12**) had about 10-fold stronger activity than **9**. On the other hand, all the carboxylic acid isomers (**10**–**13**) had stronger histaminergic H₁-blocking activity than **9**, and among them **12** was the most potent. These findings revealed that the position of the carboxy moiety is important for both activities, and the 6-position of the indole is optimum. In the next set of experiments, we introduced various possible H₁-blocking substituents onto the N₁ position of 3-(1*H*-imidazol-1-ylmethyl)-1*H*-indole-6-carboxylic acid. As shown in Table 2, the non N-substituted compound (**14**) had little effect on the arachidonate-induced aggregation or H₁-mediated tracheal contraction. Introduction of a simple alkyl chain C₃H₇- (**15**) markedly enhanced only the inhibitory effect on arachidonate-induced platelet aggregation, indicating the importance of the side chain at the N₁-position for TXA₂ synthetase inhibition. Imidazole, carboxylic acid and the N₁-substituent of **15** may interact with three sites of the enzyme, as has been postulated for TXA₂ synthetase inhibitors such as CV-4151 and Y-20811.⁹⁾ Next, possible H₁-blocking

Table 1. Structures and Pharmacological Results




No.	Position of CO ₂ H	Inhibitory effect on AIPA ^{a)} IC ₂₅ (× 10 ⁻⁶ M)	Inhibitory effect on HIC ^{b)} IC ₅₀ (× 10 ⁻⁸ M)
9	None	6.4	57.0
10	4	>100	4.7
11	5	>100	5.3
12	6	1.0	0.8
13	7	32.0	4.3
Ozagrel		3.5	>100
Pylramine		>100	0.3
Cimetidine		>100	>100

a) AIPA: arachidonate-induced aggregation of rabbit platelets. b) HIC: histamine-induced contraction of guinea pig trachea.

substituents were introduced onto the N₁-position. Both TXA₂ synthetase-inhibitory and H₁-blocking activities varied with the substituents. As regards the inhibitory effect on arachidonate-induced platelet aggregation,

Table 2. Structures and Pharmacological Results



No.	n	R	Inhibitory effect on AIPA, ^{a)} IC ₂₅ (× 10 ⁻⁶ M)	Inhibitory effect on HIC, ^{b)} IC ₅₀ (× 10 ⁻⁸ M)
14	0	H	>100	>100
15	3	H	6.5	>100
16	2		2.5	1.5
12	3		1.0	0.8
17	4		5.4	2.2
18	3		4.0	9.8
19	3		14.4	1.8
20	3		2.1	6.9
21	3		20.4	130.0
22	3		2.1	6.9
23	3		1.1	12.0
Ozagrel			3.5	>100
Pylramine			>100	0.3
Cimetidine			>100	>100

a) AIPA: arachidonate-induced aggregation of rabbit platelets. b) HIC: histamine-induced contraction of guinea pig trachea.

Table 3. Biological Activities of **12** (KY-234)

	TXA ₂ production ^{a)} IC ₅₀ (× 10 ⁻⁷ M)	Bronchoconstriction ^{b)}		
		LTD ₄	Histamine	Antigen
12 (KY-234)	0.5	6.0	2.5	6.3
Terfenadine	N.T.	>30	0.5	4.6
Ozagrel	5.0	7.1	>30	>30

a) Inhibitory effect on TXA₂ production in rabbit platelets. b) Inhibitory effect on bronchoconstriction induced by LTD₄, histamine or antigen in anesthetized guinea pigs.

Table 4. Physical Data for 3-(1*H*-imidazol-1-ylmethyl)indole Derivatives

No.	mp (°C)	Formula ^{a)}	¹ H-NMR (DMSO- <i>d</i> ₆ , δ)
6a	187—188	C ₁₄ H ₁₃ N ₃ O ₂	3.81 (3H, s), 5.47 (2H, s), 6.82 (1H, s), 6.97 (1H, s), 7.20 (1H, t), 7.49 (1H, s), 7.51 (1H, d), 7.64 (1H, d), 7.64 (1H, d), 11.60 (1H, br)
6b	185—186	C ₁₄ H ₁₃ N ₃ O ₂	3.82 (3H, s), 5.40 (2H, s), 6.85 (1H, s), 7.12 (1H, s), 7.30—7.90 (4H, m), 8.20 (1H, s), 11.20 (1H, br)
6c	187—189	C ₁₄ H ₁₃ N ₃ O ₂	3.84 (3H, s), 5.34 (2H, s), 6.83 (1H, s), 7.16 (1H, s), 7.40—7.90 (4H, m), 8.05 (1H, s), 11.50 (1H, br)
6d	165—167	C ₁₄ H ₁₃ N ₃ O ₂	3.93 (3H, s), 5.36 (2H, s), 6.84 (1H, s), 7.00—7.30 (2H, m), 7.54 (1H, d, <i>J</i> =2.4 Hz), 7.70—8.00 (3H, m), 11.10 (1H, br)
9	Oil	C ₃₂ H ₃₅ N ₅	1.70—2.50 (12H, m), 4.14 (2H, t), 4.27 (1H, s), 5.28 (2H, s), 6.81 (1H, s), 6.90—7.80 (16H, m), 8.30 (1H, s)
10	120—122	C ₃₃ H ₃₄ N ₅ NaO ₂	1.70—2.50 (12H, m), 4.25 (2H, t), 4.27 (1H, s), 5.60 (2H, s), 6.72 (1H, s), 6.9—7.6 (15H, m), 7.65 (1H, s)
11	128—130	C ₃₃ H ₃₄ N ₅ NaO ₂	1.70—2.50 (12H, m), 4.20 (2H, br t), 4.27 (1H, s), 5.33 (2H, s), 6.82 (1H, s), 7.00—7.60 (14H, m), 7.70 (1H, s), 8.15 (1H, s)
12	130—133	C ₃₃ H ₃₄ N ₅ NaO ₂	1.70—2.50 (12H, m), 4.25 (2H, br t), 4.27 (1H, s), 5.30 (2H, s), 6.80 (1H, s), 7.10—7.80 (15H, m), 8.08 (1H, s)
13	86—87	C ₃₃ H ₃₄ N ₅ NaO ₂	1.70—2.50 (12H, m), 4.37 (2H, br t), 4.24 (1H, s), 5.30 (2H, s), 6.80 (1H, s), 7.10—7.90 (16H, m)
14	222—225	C ₁₃ H ₁₁ N ₃ NaO ₂	5.35 (2H, s), 6.86 (1H, s), 7.18 (1H, s), 7.50—8.00 (4H, m), 8.05 (1H, s), 11.50 (1H, br)
15	179—181	C ₁₆ H ₁₇ N ₃ NaO ₂	0.85 (3H, t), 1.80 (2H, m), 4.19 (2H, t), 5.34 (2H, s), 6.86 (1H, s), 7.16 (1H, s), 7.50—8.00 (4H, m), 8.09 (1H, s)
16	140—142	C ₃₂ H ₃₂ N ₅ NaO ₂	2.20—2.50 (10H, m), 4.35 (2H, br t), 4.40 (1H, s), 5.33 (2H, s), 6.85 (1H, s), 7.10—7.80 (15H, m), 8.10 (1H, s)
17	100—103	C ₃₄ H ₃₆ N ₅ NaO ₂	1.40—2.50 (14H, m), 4.25 (2H, br t), 4.40 (1H, s), 5.33 (2H, s), 6.85 (1H, s), 7.10—7.80 (15H, m), 8.10 (1H, s)
18	55—58	C ₂₇ H ₂₉ ClN ₅ NaO ₂	1.60—2.08 (12H, m), 3.43 (2H, s), 4.30 (2H, br t), 5.33 (2H, s), 6.85 (1H, s), 7.20 (1H, s), 7.30 (5H, br s), 7.50—7.90 (3H, m), 8.10 (1H, s)
19	153—160	C ₃₄ H ₃₅ N ₄ NaO ₃	1.00—3.00 (13H, m), 4.30 (2H, br t), 4.50 (1H, m), 5.32 (2H, s), 6.85 (1H, s), 7.10—7.90 (15H, m), 8.10 (1H, s)
20	135—140	C ₃₄ H ₃₅ N ₄ NaO ₂	1.00—1.60 (4H, m), 1.60—3.00 (9H, m), 3.56 (1H, d), 4.30 (2H, br t), 5.32 (2H, s), 6.85 (1H, s), 6.90—7.90 (15H, m), 8.10 (1H, s)
21	68—70	C ₂₈ H ₃₂ N ₅ NaO ₃	1.80—2.60 (12H, m), 3.57 (2H, s), 3.72 (3H, s), 4.30 (2H, br t), 5.35 (2H, s), 6.85 (1H, s), 6.90 (2H, A ₂ B ₂), 7.20 (1H, s), 7.25 (2H, A ₂ B ₂), 7.60—8.00 (4H, m), 8.10 (1H, s)
22	100—102	C ₂₈ H ₃₁ N ₄ NaO ₂	1.00—3.00 (15H, m), 4.30 (2H, br t), 5.35 (2H, s), 6.85 (1H, s), 7.25 (6H, br s), 7.40—8.90 (4H, m), 8.10 (1H, s)
23	65—67	C ₂₈ H ₃₀ ClN ₄ NaO ₃	1.30—2.40 (10H, m), 2.50—2.90 (2H, m), 3.40 (1H, m), 4.30 (2H, br t), 4.46 (2H, br t), 5.32 (2H, s), 6.83 (1H, s), 7.14 (1H, s), 7.35 (4H, br s), 7.60—7.40 (4H, m), 8.09 (1H, s)

a) All elemental analyses were within ±0.4% of calculated values.

16—18, 20, 22 and 23 were slightly weaker, and 19 and 21 were markedly weaker than 12. Interestingly, a structurally small difference between 19 and 20, and between 18 and 21 resulted in a marked difference in the activity. As regards anti-histaminergic activity, 16, 17 and 19 were slightly weaker and 18 and 20—23 were markedly weaker than 12. These findings indicated that 1-[3-(4-benzhydryl-1-piperazinyl)alkyl]-3-(1*H*-imidazol-1-ylmethyl)-1*H*-indole-6-carboxylic acids have the strongest inhibitory activity on the arachidonate-induced platelet aggregation and the histamine-induced tracheal contraction. Comparison among 12, 16 and 17 indicated that optimum length of the alkyl chain is that with *n*=3.

Thus, 12 was selected for further pharmacological evaluation and was named KY-234. As shown in Table 3, KY-234 inhibited the production of TXA₂, as determined by radioimmunoassay, about 10 times more strongly than ozagrel. KY-234 also inhibited the guinea pig bronchoconstriction induced by leukotriene D₄ (LTD₄), histamine and antigen at similar doses. Terfenadine inhibited only the histamine- and antigen-induced bronchospasm, and ozagrel attenuated only the LTD₄-induced constriction. KY-234 (10⁻⁷—10⁻⁴ M) did not affect the increase of the beating rate by histamine (5 × 10⁻⁶ M) in guinea pig right atrial preparations, while

cimetidine reduced it concentration-dependently; the IC₅₀ value was about 3 × 10⁻⁶ M.

In conclusion, KY-234, a novel indole derivative, inhibits experimental asthmatic bronchospasm *via* TXA₂ synthetase-inhibitory and H₁-blocking activities. KY-234 is a candidate anti-asthmatic drug.

Experimental

Melting points were measured on a Yamato capillary melting-point apparatus without correction. Infrared (IR) spectra were recorded on a JASCO IR-810 spectrophotometer. Proton nuclear magnetic resonance (¹H-NMR) spectra were taken with a Hitachi R-1900 instrument using tetramethylsilane as an internal standard. Chemical shifts are given in ppm. The following abbreviations are used; s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. Column chromatography was performed on 70—230 mesh silica gel from Merck.

Methyl 4-Methyl-3-nitrobenzoate (2c) Concentrated HCl (7.5 ml) was added to a solution of 1c (15 g, 82.8 mmol) in MeOH (75 ml), and the reaction mixture was heated for 6 h at 80 °C. The solution was evaporated and the residue was carefully adjusted to slightly basic with saturated aqueous NaHCO₃ and extracted with AcOEt (150 ml). The AcOEt layer was washed with brine, dried (Na₂SO₄), filtered, and evaporated. The crystals were collected, washed with petroleum ether and dried to afford 2c (14 g, 87%). mp 47.5—48.5 °C. IR (Nujol) cm⁻¹: 1730, 1620, 1530. ¹H-NMR (CDCl₃) δ: 2.69 (3H, s), 3.99 (3H, s), 7.44 (1H, d, *J*=8.0 Hz), 8.15 (1H, dd, *J*=2.0, 8.0 Hz), 8.59 (1H, d, *J*=2.0 Hz).

Methyl Indole-6-carboxylate (4c) A solution of 2c (4.5 g, 23.1 mmol)

and *N,N*-dimethylformamide dimethylacetal (4.6 ml, 34.6 mmol) in DMF (11 ml) was stirred for 6.5 h at 100 °C. It was cooled, then CH₂Cl₂ (70 ml) and 5% Pd-C (0.5 g) were added and the mixture was stirred under a hydrogen atmosphere for 2 h. The reaction mixture was filtered, and CH₂Cl₂ (10 ml) and H₂O (40 ml) were added to the filtrate. The organic solution was separated and washed with 2N NaOH and brine, dried (Na₂SO₄), and evaporated. The residue was purified by chromatography (benzene) to give crystals **4c** (2.5 g, 62%). mp 79.5–80.0 °C. IR (Nujol) cm⁻¹: 1680, 1620, 1460. ¹H-NMR (CDCl₃) δ: 3.93 (3H, s), 6.59 (1H, br t), 7.34 (1H, t, *J* = 2.7 Hz), 7.65 (1H, d, *J* = 6.0 Hz), 7.85 (1H, dd, *J* = 1.5, 6.0 Hz), 8.18 (1H, d, *J* = 1.5 Hz), 8.60 (1H, br).

Methyl 3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylate (6c) A 50% aqueous HN(CH₃)₂ solution (31 ml, 0.30 mol) was added to a mixture of AcOH (65 ml), dioxane (65 ml) and 35% aqueous HCHO (24 ml, 0.30 mol) at 0–10 °C in an ice-water bath. The whole was stirred for 1 h at 8 °C, then the indole methylester **4c** (13 g, 74 mmol) was added and stirring was continued for 2 h at 0–10 °C. The reaction mixture was quenched with water (100 ml), carefully adjusted to slightly basic with 2N NaOH, and extracted three times with CHCl₃. The combined organic extracts were washed with brine, dried (Na₂SO₄), filtered, and evaporated to give an oil **5c** as a crude product. The crude product **5c** in xylene (65 ml) was treated with imidazole (25 g, 0.37 mol). The reaction mixture was stirred for 1 h at 120 °C, then poured into ice-water (65 ml). The product was collected by filtration, washed with 99.5% EtOH, and recrystallized from 99.5% EtOH to give crystals **6c** (11 g, 58%). mp 187–189 °C. IR (Nujol) cm⁻¹: 1700, 1625, 1550. ¹H-NMR (DMSO-*d*₆) δ: 3.85 (3H, s), 5.32 (2H, s), 6.86 (1H, s), 7.17 (1H, s), 7.62 (2H, s), 7.70 (1H, d, *J* = 2.0 Hz), 7.77 (1H, s), 8.08 (1H, s), 11.55 (1H, br).

Methyl 1-(3-Chloropropyl)-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylate (7c) A solution of **6c** (10 g, 39.2 mmol) in dry DMF (80 ml) was added to a suspension of sodium hydride (60% in mineral oil, 1.57 g, 39.2 mmol) in dry DMF (10 ml) with stirring in an ice-water bath. After 0.5 h, by which time gas evolution had ceased, bromochloropropane (3.9 ml, 39.2 mmol) was added. The reaction mixture was stirred at room temperature for 12 h, quenched with ice-water (100 ml) and extracted with AcOEt. The organic layer was washed with water (80 ml) and brine, and dried (Na₂SO₄). After filtration and concentration of filtrate *in vacuo*, the crude product was purified by chromatography (CHCl₃-MeOH, 20:1) to give crystals **7c** (10 g, 80%). mp 118–121 °C. IR (Nujol) cm⁻¹: 1700, 1620. ¹H-NMR (CDCl₃) δ: 2.05–2.50 (2H, m), 3.45 (2H, t, *J* = 7.0 Hz), 3.92 (3H, s), 4.39 (2H, t, *J* = 7.0 Hz), 5.28 (2H, s), 6.92 (1H, s), 7.05 (1H, s), 7.25 (1H, s), 7.45 (1H, d, *J* = 7.0 Hz), 7.55 (1H, s), 7.81 (1H, dd, *J* = 2.0, 7.0 Hz), 8.13 (1H, d, *J* = 2.0 Hz).

Methyl 1-[3-(4-Diphenylmethyl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylate (8c) K₂CO₃ (828 mg, 6.0 mmol), KI (249 mg, 1.5 mmol) and diphenylmethylpiperazine (619 mg, 3.0 mmol) were added to a solution of **7c** (1.0 g, 3.0 mmol) in dry DMF (7 ml). The mixture was stirred for 12 h at 60 °C, poured into water and extracted with AcOEt. The organic layer was washed with brine, dried (Na₂SO₄) and evaporated. The residue was purified by chromatography (CHCl₃-MeOH, 50:1) to give crystals **8c** (1.3 g, 80%). mp 147–149 °C. IR (Nujol) cm⁻¹: 1740, 1670. ¹H-NMR (CDCl₃) δ: 1.70–2.60 (4H, m), 2.41 (8H, s), 3.90 (3H, s), 4.23 (1H, s), 4.30 (2H, m), 5.24 (2H, s), 6.86 (1H, s), 7.02 (1H, s), 7.00–7.50 (10H, m), 7.18 (1H, s), 7.40 (1H, d, *J* = 7.0 Hz), 7.53 (1H, s), 7.76 (1H, dd, *J* = 2.0, 7.0 Hz), 8.12 (1H, d, *J* = 2.0 Hz).

Sodium 1-[3-(4-Benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylate (12) A mixture of **8c** (8.0 g, 14.6 mmol), MeOH (8 ml) and 2N NaOH (16 ml) was stirred for 2 h at 80 °C, then concentrated *in vacuo*. The residual solid was dissolved in EtOH, this solution was filtered and evaporated, and the residual crystals were recrystallized from EtOH to give **12** (5.0 g, 66%). mp 128–130 °C. IR (Nujol) cm⁻¹: 1660, 1580. ¹H-NMR (DMSO-*d*₆) δ: 1.70–2.50 (12H, m), 4.25 (2H, br t), 4.27 (1H, s), 5.30 (2H, s), 6.80 (1H, s), 7.05–7.80 (15H, m), 8.08 (1H, s).

Rabbit Platelet Aggregation (in Vitro) Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were obtained from rabbit blood by centrifugation at 1000 rpm for 10 min and at 3000 rpm for 10 min at 4 °C,

respectively. The platelet density of PRP was adjusted to 4 × 10⁵ cells/ml. Platelet aggregation was measured with the NKK Hema Tracer (Niko Bioscience). The PRP was incubated with KY-234 (3 × 10⁻⁷–10⁻⁴ M) or ozagrel (3 × 10⁻⁷–10⁻⁴ M) at 37 °C for 1 min, followed by addition of arachidonic acid or adenosine 5'-diphosphate (ADP).

Effect on Tracheal and Right Atrial Preparations The isolated trachea of guinea pig was cut into 16 strips and 4 tracheal chain preparations were made by connecting every 4 strips. The right atrium was excised from the isolated heart. The tracheal and atrial preparations were suspended in a 10-ml organ bath containing Krebs-Henseleit solution under 1.0 and 0.5 g of passive tension, respectively. The nutrient solution was maintained at 37 °C, pH 7.4, and continuously aerated with 95% O₂-5% CO₂. Changes in tension were measured isometrically using a force-displacement transducer (Toyo Baldwin) and recorded on an ink-writing oscillograph (NEC San-Ei Instrument). The tracheal preparations were contracted with histamine (5 × 10⁻⁶ M), and test compounds were applied cumulatively. In the right atrium, histamine (5 × 10⁻⁶ M) was applied in the absence or presence of test drugs. The beating rate of the right atrium was calculated from the recordings of spontaneous contractions.

Effect on TXA₂ Synthesis The rabbit blood was collected from the carotid artery under anesthesia and mixed with acid citrate dextrose (ACD) solution (sodium citrate 85 mM, citric acid 64 mM and dextrose 110 mM). The PRP was obtained and the platelets were washed three times with Tyrode's solution. The platelets were finally suspended in Tyrode's solution at 10⁸ platelets/ml. In the presence of aspirin (10⁻⁵ M), the platelet suspension was incubated at 37 °C for 10 min and then further incubated with PGH₂ for 30 min. TXA₂ produced was determined as TXB₂ by using a TXB₂[³H]RIA kit.

Effect on Bronchoconstriction Under anesthesia, guinea pigs were ventilated at a constant volume of 4 ml at a frequency of 40 strokes/min with an artificial respirator (Igarashi Ika Kogyo). The cannula was inserted into the jugular vein, and D-tubocurarine (0.5 mg/kg) was intravenously injected. Airway resistance was measured by the modified overflow technique as reported previously.¹⁰ Changes in insufflation pressure at a constant airflow were measured by a pressure transducer (Ugo Basile) and an amplifier (Nihon Denki Sanei) connected to the side-arm of the tracheal cannula. Bronchoconstriction was evoked by LTD₄ (0.15 mg/kg, i.v.) or histamine (10 mg/kg, i.v.) in unsensitized guinea pigs, and by BPO-BGG in passively sensitized animals. Test drugs were administered orally 1 h before the challenge with spasmogens. Passive sensitization of guinea pigs was carried out by intraperitoneal injection with anti-BPO-BGG guinea pig serum (0.2 ml/animal) 48 h before the experiment.¹¹

References and Notes

- 1) A part of this work was presented at the 113th Annual Meeting of the Pharmaceutical Society of Japan, Osaka, March 1993.
- 2) Wiech N. L., Martin J. S., *Arzneim.-Forsch.*, **32**, 1167 (1982).
- 3) Nambu F., Motoishi M., Omawari N., Okegawa T., Kawasaki A., Ikeda S., *Jpn. J. Pharmacol.*, **52**, 307 (1990).
- 4) a) Iizuka K., Akahane K., Momose D., Nakazawa M., *J. Med. Chem.*, **24**, 1139 (1981); b) Cross P. E., Dickinson R. P., Parry M. J., Randall M. J., *ibid.*, **29**, 342 (1986).
- 5) Ariens E. J., Simonis A. M., "Molecular Pharmacology," Vol. 1, Academic Press, Orlando, 1964, p. 287.
- 6) Naito J., Komatsu H., Ujiie A., Hamano S., Kubota T., Tsuboshima M., *Eur. J. Pharmacol.*, **91**, 41 (1983).
- 7) Chand N., Eyre P., *Agents Actions*, **5**, 277 (1975).
- 8) Clark R. D., Repke D. B., *Heterocycles*, **22**, 195 (1984).
- 9) a) Kato K., Ohkawa S., Terao S., Terashita Z., Nishikawa K., *J. Med. Chem.*, **28**, 287 (1985); b) Tsuruta M., Mikashima H., Ooe T., Kawasaki K., Setoguchi S., Naka Y., Tahara T., *Yakugaku Zasshi*, **109**, 33 (1989).
- 10) Nakamura S., Yamamura H., Kohno S., Ohata K., *Jpn. J. Allergol.*, **39**, 1621 (1990).
- 11) a) Levine B. B., Redmond A. P., *J. Clin. Invest.*, **47**, 556 (1968); b) Levine B. B., Chang H., Vaz N. M., *J. Immunology*, **106**, 29 (1971).